1. Introduction {#sec1}
===============

Ovarian cancer is the leading cause of the female reproductive system, with over 220,000 new cases and over 140,000 deaths worldwide in 2008 \[[@B1]\]. As most of the carcinomas, ovarian cancer is a multifactorial disease. Genetic factors are considered to influence the susceptibility of glioma genetic factors which all play significant roles in its susceptibility \[[@B2]\]. The genetic basis of ovarian carcinogenesis has been investigated in many studies.*BRCA1*,*BRCA2*,*MLH1*,*MSH2*,*SMAD6*,*RAD51C*,*RAD51D*,*RB1*,*LIN28B*,*CASP8*, and*MTDH* have all been implicated \[[@B3]--[@B11]\]. Recently, several common susceptibility alleles in four loci to be strongly associated with ovarian cancer risk have been found in three genome-wide association studies (GWAS) \[[@B12]--[@B14]\]. Examination of gene polymorphisms may explain individual differences in cancer risk \[[@B15]\].

*XRCC3* (X-ray repair cross-complementing group 3) belongs to a family of genes responsible for repairing DNA double strand breaks caused by normal metabolic processes or exposure to ionizing radiation \[[@B16]\].*XRCC3* interacts and stabilizes Rad51 and involves in HRR (homologous recombinational repair) for DBSs (double strand breaks of DNA) and cross-link repair in mammalian cells \[[@B17], [@B18]\]. The SNP rs861539 lead to Thr241Met amino acid substitution, that may affect the function and/or its interaction with other proteins involved in DNA damage and repair \[[@B17], [@B19]\]. The SNP rs1799794 (4541*A* \>*G*) is located in 5′UTR and the SNP rs1799796 (17893*A* \>*G*) is located in intron 5 \[[@B20]\]. So the two SNPs do not change the proteins of*XRCC3*.*XRCC3* polymorphism was associated with the risks of many cancers, such as lung cancer, breast cancer, and head and neck cancer \[[@B21]--[@B24]\]. The association between*XRCC3* polymorphism and ovarian cancer has been studied \[[@B20], [@B25]--[@B29]\]; however, those experimental results remain confusing. To summarize the effect of the*XRCC3* polymorphism on the risk for ovarian cancer, we performed a meta-analysis.

2. Methods {#sec2}
==========

2.1. Search and Selection Process {#sec2.1}
---------------------------------

The search of the PubMed database was performed using the following keywords: "X-ray repair cross-complementing group 3," "*XRCC3*," "rs861539," "T241M," "rs1799794," "a4541g," "rs1799796," "a17893g," "polymorphism," "ovarian cancer," and their combination. Two authors (Yuan and Wang) independently checked all the references retrieved to assess their appropriateness for the inclusion in this meta-analysis. In addition, we checked all the references cited in the articles and relevant reviews. For overlapping and republished studies, only the study with the largest samples was included. If an article reported results including different studies, each study was treated as a separate comparison in our meta-analysis.

Included studies met 3 criteria:evaluating the association between*XRCC3* polymorphisms and ovarian cancer risk;using sufficient published data to enable estimation of an odds ratio (OR) with its 95% confidence interval (CI);using respective or prospective cohort case-control studies.

2.2. Data Extraction {#sec2.2}
--------------------

Two authors (Yuan and Wang) independently extracted data from selected articles according to the inclusion criteria and reached a consensus on all items.

The following information was extracted from each study if available: the first author, year of publication, countries, area of the cases, the ethnicity of the population, the cases source, the sample type of cases, the numbers of cases and controls, and the genotype distributions of*XRCC3* in both cases and controls.

2.3. Quality Score Assessment {#sec2.3}
-----------------------------

Two authors independently evaluated the quality of the 8 studies according to the scale for quality assessment ([Table 1](#tab1){ref-type="table"}), which has been described previously \[[@B30], [@B31]\]. Quality score assessment was performed according to "source of cases," "source of controls," "specimens of cases for determining genotypes," "Hardy-Weinberg equilibrium in controls," and "total sample size." Total scores ranged from 0 (worst) to 15 (best). Studies scoring ≥10 were defined as "high quality," and those \<10 were defined as "low quality."

2.4. Statistical Analysis {#sec2.4}
-------------------------

Pooled ORs with 95% CIs were calculated to access the strength of association between*XRCC3* polymorphism and ovarian cancer susceptibility, according to the genotype frequencies of cases and controls groups \[[@B32]\]. *P* \< 0.05 was considered statistically significant; all tests and CIs were two sided. If the heterogeneity was significant, the pooled ORs were initially measured by the random effects model. Else, the fixed-effects model was chosen \[[@B33]\].

The*XRCC3* polymorphism and ovarian cancer risk were performed for a homozygote comparison (T2T2 versus T1T1), heterozygote comparison (T1T2 versus T1T1), dominant genetic model (T1T2+T2T2 versus T1T1), and the recessive genetic model (T2T2 versus T1T1+T1T2). In addition, sensitivity analysis was performed by omitting each study. Publication bias was estimated using a funnel plot. The degree of asymmetry was examined by t Egger\'s test (*P* \< 0.05 was considered significant publication bias) \[[@B34]\]. The analysis was carried out using Review Manager statistical software (RevMan version 5.0.17.0; The Nordic Cochrane Center, Rigshospitalet, Copenhagen, Denmark) and STATA software (version 11.2, Stata Corporation, College Station, TX, USA). Hardy-Weinberg equilibrium (HWE) was calculated using a web-based statistical tool (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>).

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

Through the literature search, 13 articles were found. Eight articles \[[@B35]--[@B42]\] were excluded as irrelevant study. One study \[[@B26]\] was excluded because it was carried out on overlapping populations with another, more samples eligible study \[[@B27]\]. Total 4 articles including 8 studies were selected on 5,302 ovarian cancer cases and 8,075 controls for 3 SNPs \[[@B20], [@B25]--[@B27]\] ([Figure 1](#fig1){ref-type="fig"}). These studies were all published in English. The main characteristics of the 4 studies are shown in [Table 2](#tab2){ref-type="table"}. All subjects in these studies were Caucasians. The sample sizes (cases and controls) ranged from 1,478 to 5,906. Quality scores for all studies were high quality (≥10). Distribution of rs861539 polymorphisms genotype frequencies among ovarian cancer cases and controls of the 2 studies is shown in [Table 3](#tab3){ref-type="table"}. Distribution of rs1799794 polymorphisms genotype frequencies is shown in [Table 4](#tab4){ref-type="table"} and distribution of rs1799796 polymorphisms genotype frequencies is shown in [Table 5](#tab5){ref-type="table"}.

Hardy-Weinberg disequilibrium of genotype frequencies among the controls was calculated in three studies.

3.2. Association of Individual Polymorphisms with Ovarian Cancer {#sec3.2}
----------------------------------------------------------------

The heterogeneity analysis has been carried out. As it was shown in Tables [3](#tab3){ref-type="table"}, [4](#tab4){ref-type="table"}, and [5](#tab5){ref-type="table"}, the heterogeneities of 3 SNPs are all not significant. So the fixed-effects model was chosen for 3 SNPs.

The meta-analysis results of*XRCC3* rs861539 polymorphisms are shown in [Table 3](#tab3){ref-type="table"}. No statistically significant associations between*XRCC3* rs861539 polymorphisms and ovarian cancer risk were observed in any genetic models (T2T2 versus T1T1: OR = 0.95, 95% CI = 0.85--1.06, *P* = 0.37; T1T2 versus T1T1: OR = 0.95, 95% CI = 0.88--1.03, *P* = 0.22; T1T2+T2T2 versus T1T1: OR = 0.95, 95% CI = 0.88--1.02, *P* = 0.19; T2T2 versus T1T1+T1T2: OR = 0.97, 95% CI = 0.88--1.08, *P* = 0.63).

For*XRCC3* rs1799794 polymorphisms, two studies \[[@B16], [@B18], [@B20], [@B21], [@B23], [@B24]\] (3,119 cases and 6,207 controls) were eligible. The meta-analysis results of rs1799794 polymorphisms are shown in [Table 4](#tab4){ref-type="table"}. We observed a statistically significant correlation with ovarian cancer risk using the homozygote comparison (T2T2 versus T1T1: OR = 0.70, 95% CI = 0.54--0.90, *P* = 0.005), heterozygote comparison (T1T2 versus T1T1: OR = 1.10, 95% CI = 1.00--1.21, *P* = 0.04), and the recessive genetic model (T2T2 versus T1T1+T1T2 : OR = 0.67, 95% CI = 0.52--0.87, *P* = 0.002). However, no statistically significant associations were observed in dominant genetic model (T1T2+T2T2 versus T1T1: OR = 1.06, 95% CI = 0.96--1.15, *P* = 0.24).

For*XRCC3* rs1799796 polymorphisms, the meta-analysis results were shown in [Table 4](#tab4){ref-type="table"}. We observed a statistically significant correlation with ovarian cancer risk using the heterozygote comparison (T1T2 versus T1T1: OR = 0.91, 95% CI = 0.83--0.99, *P* = 0.04). However no statistically significant associations were observed in homozygote comparison (T2T2 versus T1T1: OR = 1.07, 95% CI = 0.93--1.24, *P* = 0.33), dominant genetic model (T1T2+T2T2 versus T1T1: OR = 0.94, 95% CI = 0.86--1.03, *P* = 0.16), and the recessive genetic model (T2T2 versus T1T1+T1T2: OR = 1.13, 95% CI = 0.98--1.29, *P* = 0.08).

3.3. Publication Bias and Sensitivity Analysis {#sec3.3}
----------------------------------------------

The publication bias was tested by Begg\'s funnel plot and Egger\'s test for three SNPs. Egger\'s test results did not show any evidence of publication bias for any of the genetic models of the three SNPs (data not shown). The shape of the four Begg\'s funnel plots showed no evidence of obvious asymmetry of the three SNPs (data not shown).

In the sensitivity analysis, the corresponding pooled ORs were not altered, when the fixed-effects model was changed to random-effects model. So it revealed that the results of this meta-analysis were stable.

4. Discussion {#sec4}
=============

The*XRCC3* gene is required for genomic stability \[[@B36]\]. It was reported that the*XRCC3* polymorphism increased the risk of many cancers, including ovarian cancer \[[@B36]\]. However, the results have been inconsistent. We preformed the meta-analysis including 5,302 ovarian cancer cases and 8,075 controls for 3 SNPs of*XRCC3*.

For rs861539 polymorphisms, no correlation with ovarian cancer risk was observed in any genetic models. However, For*XRCC3* rs1799794 and rs1799796 polymorphisms, we observed a statistically significant correlation with ovarian cancer risk. It was shown that the difference between different SNP sites was considerable for*XRCC3*.

All of the literature was of high quality. All study subjects were Caucasian. The global multicenter studies can provide more valuable conclusions. So further studies should be done to explore the possible relationships between*XRCC3* polymorphisms and ovarian cancer risk in other ethnicities.

In conclusion, this meta-analysis shows that the*XRCC3* were associated with ovarian cancer risk overall for Caucasians. Asian and African populations should be further studied.
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###### 

Scale for quality assessment.

  Criteria                                       Score
  ---------------------------------------------- -------
  Source of cases                                 
   Population or cancer registry                 3
   Mixed (hospital and cancer registry)          2
   Hospital                                      1
   Other                                         0
  Source of controls                              
   Population based                              3
   Volunteers or Blood bank                      2
   Hospital based (cancer-free patients)         1
   Not described                                 0
  Specimens of cases for determining genotypes    
   Blood or normal tissues                       3
   Mixed (blood and archival paraffin blocks)    1
   Tumor tissues or exfoliated cells of tissue   0
  Hardy-Weinberg equilibrium in controls          
   Hardy-Weinberg equilibrium                    3
   Hardy-Weinberg disequilibrium                 0
  Total sample size                               
   ≥1000                                         3
   ≥500 and \<1000                               2
   ≥200 and \<500                                1
   \<200                                         0

###### 

Main characteristics of the studies included in the meta-analysis.

  First author         Year   Country             Area of the cases                                                        Ethnicity   Cases source                           Controls source   Sample type of cases                         Total cases/controls   Quality score
  -------------------- ------ ------------------- ------------------------------------------------------------------------ ----------- -------------------------------------- ----------------- -------------------------------------------- ---------------------- ---------------
  Auranen \[[@B20]\]   2005   Mixed (UK-USA)      Royal Marsden Hospital in London and 6 counties in Northern California   Caucasian   Mixed (hospital and cancer registry)   Population        Blood                                        1665/4241              14
                                                                                                                                                                                                                                                                    
  Beesley \[[@B26]\]   2007   Australia           New South Wales and Victorian Cancer Registries                          Caucasian   Cancer registry                        Population        Blood                                        731/747                15
                                                                                                                                                                                                                                                                    
  Quaye \[[@B25]\]     2009   Mixed (DK-UK-USA)   MALOVA from Denmark-SEARCH from the UK-and GEOCS from the USA.           Caucasian   Mixed (hospital and cancer registry)   Population        Blood                                        1461/2299              14
                                                                                                                                                                                                                                                                    
  Webb \[[@B27]\]      2005   Australia           New South Wales-Victoria and Queensland                                  Caucasian   Mixed (hospital and cancer registry)   Volunteers        Mixed (blood and archival paraffin blocks)   1445/788               12

###### 

Distribution of *XRCC3* rs861539 genotype among ovarian cancer cases and controls included in the meta-analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First\               Year   Genotypes distribution\   Genotypes distribution\     P-HWE\     T2T2 versus T1T1   T1T2 versus T1T1   T1T2+T2T2 versus T1T1   T2T2 versus T1T1+T1T2                                                                                                                                  
  author                      (Case source)             (Controls source)         (Controls)                                                                                                                                                                                                                        
  -------------------- ------ ------------------------- ------------------------- ------------ ------------------ ------------------ ----------------------- ----------------------- --------------------- ------------ --------------------- ------------ --------------------- ------------ --------------------- ------------
  Auranen \[[@B20]\]   2005   676                       762                       227          1712               1946               583                     Yes                     0.99 \[0.83, 1.18\]   0.88         0.99 \[0.88, 1.12\]   0.89         0.99 \[0.88, 1.11\]   0.87         0.99 \[0.84, 1.17\]   0.91

  Beesley \[[@B26]\]   2007   291                       339                       101          288                351                108                     Yes                     0.93 \[0.67, 1.27\]   0.63         0.96 \[0.77, 1.19\]   0.69         0.95 \[0.77, 1.17\]   0.62         0.95 \[0.71, 1.27\]   0.72

  Quaye \[[@B25]\]     2009   545                       612                       175          784                958                282                     Yes                     0.89 \[0.72, 1.11\]   0.31         0.92 \[0.79, 1.07\]   0.27         0.91 \[0.79, 1.05\]   0.21         0.93 \[0.76, 1.14\]   0.51

  Webb \[[@B27]\]      2005   591                       656                       198          307                375                106                     Yes                     0.97 \[0.74, 1.28\]   0.83         0.91 \[0.75, 1.10\]   0.32         0.92 \[0.77, 1.10\]   0.37         1.02 \[0.79, 1.32\]   0.87

                                                                                                                                                                                                                                                                                                                    

  Total                       2103                      2369                      701          3091               3630               1079                                            0.95 \[0.85, 1.06\]   0.37         0.95 \[0.88, 1.03\]   0.22         0.95 \[0.88, 1.02\]   0.19         0.97 \[0.88, 1.08\]   0.63

                                                                                                                                                                                     **Test  for ** \      *P* = 0.91   **Test  for** \       *P* = 0.88   **Test  for** \       *P* = 0.82   **Test  for** \       *P* = 0.77
                                                                                                                                                                                     **heterogeneity**                  **heterogeneity**                  **heterogeneity**                  ** heterogeneity**    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Distribution of *XRCC3* rs1799794 genotype among ovarian cancer cases and controls included in the meta-analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author         Year   Genotypes distribution\   Genotypes distribution\     P-HWE\     T2T2 versus T1T1   T1T2 versus T1T1   T1T2+T2T2 versus T1T1   T2T2 versus T1T1+T1T2                                                                                                                                  
                              (Case source)             (Controls source)         (Controls)                                                                                                                                                                                                                        
  -------------------- ------ ------------------------- ------------------------- ------------ ------------------ ------------------ ----------------------- ----------------------- --------------------- ------------ --------------------- ------------ --------------------- ------------ --------------------- ------------
  Auranen \[[@B20]\]   2005   1060                      550                       48           2551               1188               161                     Yes                     0.72 \[0.52, 1.00\]   0.048        1.11 \[0.98, 1.26\]   0.087        1.07 \[0.95, 1.20\]   0.29         0.69 \[0.50, 0.96\]   0.027

  Quaye \[[@B25]\]     2009   940                       484                       37           1505               713                89                      Yes                     0.67 \[0.45, 0.99\]   **0.04**     1.09 \[0.94, 1.25\]   0.25         1.04 \[0.91, 1.19\]   0.57         0.65 \[0.44, 0.96\]   0.027

                                                                                                                                                                                                                                                                                                                    

  Total                       2000                      1034                      85           4056               1901               250                                             0.70 \[0.54, 0.90\]   0.005        1.10 \[1.00, 1.21\]   0.04         1.06 \[0.96, 1.15\]   0.24         0.67 \[0.52, 0.87\]   0.002

                                                                                                                                                                                     **Test  for ** \      *P* = 0.77   **Test  for**  \      *P* = 0.83   **Test  for**  \      *P* = 0.78   **Test  for**  \      *P* = 0.80
                                                                                                                                                                                     **heterogeneity**                  **heterogeneity**                  **heterogeneity**                  **heterogeneity**     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Distribution of *XRCC3* rs1799796 genotype among ovarian cancer cases and controls included in the meta-analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author         Year   Genotypes distribution\   Genotypes distribution\   P-HWE\       T2T2 versus T1T1   T1T2 versus T1T1   T1T2+T2T2 versus T1T1   T2T2 versus T1T1+T1T2                                                                                                                                  
                              (Case source)             (Controls source)         (Controls)                                                                                                                                                                                                                        
  -------------------- ------ ------------------------- ------------------------- ------------ ------------------ ------------------ ----------------------- ----------------------- --------------------- ------------ --------------------- ------------ --------------------- ------------ --------------------- ------------
  Auranen \[[@B20]\]   2005   769                       692                       203          1757               1776               433                     Yes                     1.07 \[0.89, 1.29\]   0.47         0.89 \[0.79, 1.01\]   0.062        0.93 \[0.83, 1.04\]   0.188        1.13 \[0.95, 1.35\]   0.17

  Quaye \[[@B25]\]     2009   676                       608                       177          1040               1006               253                     Yes                     1.08 \[0.87, 1.33\]   0.5          0.93 \[0.81, 1.07\]   0.31         0.96 \[0.84, 1.09\]   0.536        1.11 \[0.91, 1.37\]   0.30

                                                                                                                                                                                                                                                                                                                    

  Total                       1445                      1300                      380          2797               2782               686                                             1.07 \[0.93, 1.24\]   0.33         0.91 \[0.83, 0.99\]   0.04         0.94 \[0.86, 1.03\]   0.16         1.13 \[0.98, 1.29\]   0.08

                                                                                                                                                                                     **Test  for ** \      *P* = 0.97   **Test  for ** \      *P* = 0.65   **Test  for ** \      *P* = 0.69   **Test  for ** \      *P* = 0.90
                                                                                                                                                                                     **heterogeneity**                  **heterogeneity**                  **heterogeneity**                  **heterogeneity**     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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